Following on disappointing results in the phase 2 trial of its pain control medication brivoligide, San Francisco-based Adynxx has announced it will merge with Alliqua BioMedical and be listed on the NASDAQ exchange.

The new company will continue the Adynxx name and is seeking to raise cash to continue midphase clinical trials for brivoligide, reported FierceBiotech‘s Nick Paul Taylor, even though it showed no significant pain relief over placebo in its last phase 2 trial.

Learn more here, on FierceBiotech.